Clinical data | |
---|---|
Trade names | Demigran, Leomigran |
Other names | WG-537; 6α-(Trifluoromethyl)-17α-acetoxyprogesterone; 6α-(Trifluoromethyl)-17α-acetoxypregn-4-ene-3,20-dione |
Routes of administration | By mouth [1] |
Drug class | Progestogen; Progestin; Progestogen ester |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.012.343 |
Chemical and physical data | |
Formula | C24H31F3O4 |
Molar mass | 440.503 g·mol−1 |
3D model ( JSmol) | |
| |
|
Flumedroxone acetate, sold under the brand names Demigran and Leomigran, is a progestin medication which is or has been used as an antimigraine agent. [2] [3] [4] It is taken by mouth. [1]
Flumedroxone acetate has been assessed in over 1,000 patients for the treatment of migraine, with effectiveness ranging from excellent to less than that of the reference antimigraine drug methysergide. [5] Other progestogens including medroxyprogesterone acetate, lynestrenol, allylestrenol, dydrogesterone, and normethandrone have also been found to be effective for migraine in a high percentage of women. [5]
In accordance with its progestogenic activity, flumedroxone acetate produces menstrual irregularities, namely polymenorrhea, and breast tension as side effects in women. [5] [6] [7]
Flumedroxone acetate is said to have weak or slight progestogenic activity without other hormonal activity, including no estrogenic, antiestrogenic, androgenic, anabolic, or glucocorticoid activity. [5] [1]
Flumedroxone acetate, also known as 6α-(trifluoromethyl)-17α-acetoxyprogesterone or as 6α-(trifluoromethyl)-17α-acetoxypregn-4-ene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [2] It is specifically a derivative of 17α-hydroxyprogesterone with a trifluoromethyl group at the C6α position and an acetate ester attached to the C17α hydroxyl group. [3] The medication is the C17α acetate ester of flumedroxone (6α-(trifluoromethyl)-17α-hydroxyprogesterone) and the C6α trifluoromethyl derivative of hydroxyprogesterone acetate (17α-acetoxyprogesterone). [2]
Flumedroxone acetate was introduced for medical use in the 1960s. [4]
Flumedroxone is the INN and BAN of the free alcohol form of the drug, flumedroxone. [2] Flumedroxone acetate is also known by its developmental code name WG-537. [2]
Flumedroxone acetate is or has been marketed under the brand names Demigran and Leomigran. [2] [4]
Flumedroxone acetate is or has been marketed in Europe. [4]
Lundberg (1969) recommended the oral application of a steroid (flumedroxone) which has only a weak progesterone effect and does not display any other gonadotropic effects.
Clinical data | |
---|---|
Trade names | Demigran, Leomigran |
Other names | WG-537; 6α-(Trifluoromethyl)-17α-acetoxyprogesterone; 6α-(Trifluoromethyl)-17α-acetoxypregn-4-ene-3,20-dione |
Routes of administration | By mouth [1] |
Drug class | Progestogen; Progestin; Progestogen ester |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.012.343 |
Chemical and physical data | |
Formula | C24H31F3O4 |
Molar mass | 440.503 g·mol−1 |
3D model ( JSmol) | |
| |
|
Flumedroxone acetate, sold under the brand names Demigran and Leomigran, is a progestin medication which is or has been used as an antimigraine agent. [2] [3] [4] It is taken by mouth. [1]
Flumedroxone acetate has been assessed in over 1,000 patients for the treatment of migraine, with effectiveness ranging from excellent to less than that of the reference antimigraine drug methysergide. [5] Other progestogens including medroxyprogesterone acetate, lynestrenol, allylestrenol, dydrogesterone, and normethandrone have also been found to be effective for migraine in a high percentage of women. [5]
In accordance with its progestogenic activity, flumedroxone acetate produces menstrual irregularities, namely polymenorrhea, and breast tension as side effects in women. [5] [6] [7]
Flumedroxone acetate is said to have weak or slight progestogenic activity without other hormonal activity, including no estrogenic, antiestrogenic, androgenic, anabolic, or glucocorticoid activity. [5] [1]
Flumedroxone acetate, also known as 6α-(trifluoromethyl)-17α-acetoxyprogesterone or as 6α-(trifluoromethyl)-17α-acetoxypregn-4-ene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [2] It is specifically a derivative of 17α-hydroxyprogesterone with a trifluoromethyl group at the C6α position and an acetate ester attached to the C17α hydroxyl group. [3] The medication is the C17α acetate ester of flumedroxone (6α-(trifluoromethyl)-17α-hydroxyprogesterone) and the C6α trifluoromethyl derivative of hydroxyprogesterone acetate (17α-acetoxyprogesterone). [2]
Flumedroxone acetate was introduced for medical use in the 1960s. [4]
Flumedroxone is the INN and BAN of the free alcohol form of the drug, flumedroxone. [2] Flumedroxone acetate is also known by its developmental code name WG-537. [2]
Flumedroxone acetate is or has been marketed under the brand names Demigran and Leomigran. [2] [4]
Flumedroxone acetate is or has been marketed in Europe. [4]
Lundberg (1969) recommended the oral application of a steroid (flumedroxone) which has only a weak progesterone effect and does not display any other gonadotropic effects.